tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Capricor Therapeutics initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst Matthew Venezia initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $20 price target adding a “Speculative” modifier to its rating, calling Capricor “a promising story with newly-added reagulatory risk but solid fundamentals,” which might make its relatively low current valuation “attractive to the right investor.” The firm’s 12- to 18-month valuation of Capricor shares is based on a sum-of-the parts analysis, including Deramiocel for DMD being valued at $15.00 per share, the analyst noted.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1